An approach to the medical marijuana controversy.
The use of smoked marijuana as a therapeutic agent is presently a matter of considerable debate in the United States. Many people suffering from a variety of disorders maintain that it is necessary for their adequate treatment. Yet, the evidence to support claims is insufficient for FDA approval. An interim solution is proposed which would allow patients referred by their physicians to participate in a 6-month program of legal marijuana availability, similar to the 'compassionate IND' program of a number of years ago. A technique similar to that used for post-marketing surveillance is proposed for obtaining quantitative data for a limited number of potential indications. These are: (1) nausea and vomiting associated with cancer chemotherapy or other causes, (2) weight loss associated with debilitating illnesses, (3) spasticity secondary to neurological diseases, and (4) chronic pain syndromes.
Hollister
L E
LE
University of Texas Medical Branch, UT Harris County Psychiatric Center, Houston 77021, USA.
D002188:Cannabis / Q000627:therapeutic use*; D017277:Drug Approval; D019247:HIV Wasting Syndrome / Q000517:prevention & control; D006801:Humans; D008385:Marijuana Smoking / Q000331:legislation & jurisprudence; D009128:Muscle Spasticity / Q000517:prevention & control; D009325:Nausea / Q000517:prevention & control; D010146:Pain / Q000517:prevention & control; D008517:Phytotherapy; D012017:Referral and Consultation; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000517:prevention & control